2019
Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer
Kim I, Kim S, Srivastava A, Saraiya B, Mayer T, Kim W, Kim I. Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer. BMC Urology 2019, 19: 33. PMID: 31060606, PMCID: PMC6501301, DOI: 10.1186/s12894-019-0453-9.Peer-Reviewed Original ResearchConceptsCastration-resistant prostate cancerDDR pathway alterationProstate cancerPathway alterationsMetastatic castration-resistant prostate cancerSerum prostate-specific antigenHigh-risk diseaseMetastatic prostate cancerLower overall survivalPathway gene mutationsProstate-specific antigenPotential therapeutic targetUnited States National Cancer InstituteNational Cancer InstituteCRPC patientsCancer Genome AtlasOverall survivalSimilar incidenceTumor stageUnivariate analysisCancer InstituteTherapeutic targetSpecific antigenPARP inhibitorsPathway status
2017
Predicting clinically significant prostate cancer based on pre-operative patient profile and serum biomarkers
Faiena I, Kim S, Farber N, Kwon Y, Shinder B, Patel N, Salmasi A, Jang T, Singer E, Kim W, Kim I. Predicting clinically significant prostate cancer based on pre-operative patient profile and serum biomarkers. Oncotarget 2017, 5: 109783-109790. PMID: 29312648, PMCID: PMC5752561, DOI: 10.18632/oncotarget.21297.Peer-Reviewed Original ResearchClinical Gleason scoreBody mass indexProstate-specific antigenSignificant prostate cancerProstate acid phosphatasePreoperative prostate-specific antigenGleason scoreProstate cancerSerum biomarkersProstate weightParathyroid hormoneTotal prostate-specific antigenBias-corrected areaMultiple preoperative factorsPreoperative factorsOncologic characteristicsPatient characteristicsProstatectomy databaseMass indexRisk stratificationClinical stageUnivariate analysisPatient profilesHormone profilesMultivariate analysis